Kadono, Yoshifumi, Shohei Kawaguchi, Takahiro Nohara, Kazuyoshi Shigehara, Kouji Izumi, Taiki Kamijima, Chikashi Seto, et al. 2021. “Favorable Response of Pembrolizumab As Second-Line Therapy for Advanced Urothelial Carcinoma With Only Small Lesions to Not Be Considered Measurable by RECIST”. Urology Journal 19 (03):202-8. https://doi.org/10.22037/uj.v19i03.6652.